Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 30;2(1):e000975.
doi: 10.1136/bmjph-2024-000975. eCollection 2024 Jun.

Assessing the long-term economic impact of wheezing episodes after severe RSV disease in children from Argentina: a cost of illness analysis

Julia Dvorkin  1   2 , Clint Pecenka  3 , Emiliano M Sosa  1 , Andrea Sancilio  1 , Karina Dueñas  1 , Andrea Rodriguez  1 , Carlos Rojas-Roque  4 , Patricia B Carruitero  5 , Ranju Baral  3 , Elisabeth Vodicka  3 , Fernando P Polack  1 , Romina Libster #  1 , Mauricio T Caballero #  1   2
Affiliations

Assessing the long-term economic impact of wheezing episodes after severe RSV disease in children from Argentina: a cost of illness analysis

Julia Dvorkin et al. BMJ Public Health. .

Abstract

Introduction: There is lack of available data on the economic burden of wheezing episodes after severe respiratory syncytial virus (RSV) infection. This study aimed to assess the cost incurred for wheezing episodes after a severe RSV infection in children from Argentina, considering both the public health system and societal perspectives.

Methods: A prospective cohort was conducted from 2014 to 2022 to assess the cost of illness of wheezing episodes after severe RSV disease in children from Buenos Aires, Argentina. Direct medical and non-medical costs were estimated, along with indirect costs per episode and patient. Data pertaining to healthcare resource utilisation, indirect expenses and parental out-of-pocket costs were obtained. The overall cost per hospitalisation and health visits was calculated. Costs were quantified in US dollars using the average exchange rate on the specific date of data collection.

Results: A total of 256 infants experienced severe RSV disease during their first year of life and were followed over a 5-year period in Buenos Aires. Overall, 150 children between 12 and 60 months presented 429 wheezing episodes. The median number of wheezing episodes per patient was 5 (IQR 3-7). The mean cost per wheezing episode was US$191.01 (95% CI 166.37 to 215.64). The total cost per episode of wheezing was significantly higher (p<0.001) in infants under 12 months of age (207.43, 95% CI 154.3 to 260.6) compared with older toddler. The average cumulative cost associated to wheezing per patient was US$415.99 (95% CI 313.35 to 518.63). Considering both acute RSV disease and long-term wheezing outcomes, the cumulative mean cost per patient was US$959.56 (95% CI 832.01 to 1087.10).

Conclusions: This study reveals the economic impact of prolonged wheezing resulting from severe acute RSV infection on Argentina's public health system and society. The estimates obtained serve as valuable inputs for informing cost-effectiveness analyses of upcoming RSV preventive interventions.

Keywords: Epidemiology; Public Health; economics.

PubMed Disclaimer

Conflict of interest statement

FPP reports grants and personal fees from Janssen, Pfizer, Sanofi and Merck, outside the submitted work. RL reports grants and/or personal fees from Merck, Pfizer and Janssen, outside the submitted work. EV was employed at PATH during her collaborations on this study; she is currently an employee of Pfizer.

References

    1. Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399:2047–64. doi: 10.1016/S0140-6736(22)00478-0. - DOI - PMC - PubMed
    1. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390:946–58. doi: 10.1016/S0140-6736(17)30938-8. - DOI - PMC - PubMed
    1. Mazur NI, Löwensteyn YN, Willemsen JE, et al. Global respiratory syncytial virus–related infant community deaths. Clin Infect Dis. 2021;73:S229–37. doi: 10.1093/cid/ciab528. - DOI - PMC - PubMed
    1. Dvorkin J, De Luca J, Alvarez-Paggi D, et al. Responding to higher-than-expected infant mortality rates from respiratory syncytial virus (RSV): improving treatment and reporting strategies. Infect Drug Resist. 2023;16:595–605. doi: 10.2147/IDR.S373584. - DOI - PMC - PubMed
    1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–55. doi: 10.1016/S0140-6736(10)60206-1. - DOI - PMC - PubMed

LinkOut - more resources